Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Transitional Cell 2

Interventions

toripalimab 4pembrolizumab 4Gemcitabine 4tislelizumab 2durvalumab 2Nivolumab 2Cisplatin 2Carboplatin 2AZD4547 2tipifarnib 1tesetaxel 1sapanisertib 1regorafenib 1pyrotinib 1nintedanib 1famitinib 1disitamab vedotin 1camrelizumab 1bintrafusp alfa protein, human 1atezolizumab 1anlotinib 1aldesleukin 1advexin 1Vitamin B 12 1Trastuzumab 1Taxes 1Surgical Procedures, Operative 1Saline Solution 1Resistance Training 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Transitional Cell × AZD4547 × Clear all
NCT05775874 2023-03-20

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Abbisko Therapeutics Co, Ltd

Phase 2 Unknown
80 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05086666 2021-10-21

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Abbisko Therapeutics Co, Ltd

Phase 1/2 Unknown
108 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡